摘要
目的:探讨在131I治疗甲亢之前服用甲巯咪唑(MMI)对131I疗效的影响。方法:甲亢患者201例随机分为两组,对照组115例,未接受任何抗甲状腺药物治疗或药物治疗后但已停药3~4周,直接接受131I治疗;观察组86例接受甲巯咪唑治疗1月以上,再接受131I治疗1月后逐渐停药。治疗后6月,根据患者FT3、FT4、TSH水平评价疗效。结果:在治疗后6个月,对照组和观察组患者中分别有21例(18.3%)及14例(16.3%)仍处于甲亢,有12(10.4%)及8例(9.3%)发生甲低,有82例(71.3%)及64例(74.4%)患者甲状腺功能维持正常。总的治愈率分别为81.7%(94例)及83.7%(72例)。两组疗效比较无统计学性差异(P>0.05)。结论:在适量增加131I治疗剂量的条件下,治疗前应用甲巯咪唑治疗不会影响131I的疗效。
Objective:To discuss the effects of taking methimazole before 131I treatment for hyperthyroidism Methods:201patients with hyperthyroidism disease were randomly assigned to the control group with 115cases treated with 131I alone and the observation group with 86cases treated with methimazole crystalline(MMI)for a month before the beginning of 131I therapy.All the patients were examined after six months treatment to evaluate curative effects based on levels of FT3,FT4 and TSH of the patients.Results:The cure of hyperthyroidism occurred in 94of 115patients(81.7%)treated with 131I alone and in 83of 86patients(83.7%)treated with 131I plus methimazole crystalline(MMI).There were no significant differences in the cure rate between the two groups.Conclusion:The additional use of methimazole crystalline before 131I therapy does not affect the efficacy of 131I in the treatment of hyperthyroidism.
基金
湖北省教育厅科学技术研究项目(B20102116)
